Targeting cell cycle and hormone receptor pathways in cancer.
about
The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisTargeting the adaptive molecular landscape of castration-resistant prostate cancerLoss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.Integrative clinical genomics of advanced prostate cancer.CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancerPalbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.The history and future of targeting cyclin-dependent kinases in cancer therapy.Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingNovel actions of next-generation taxanes benefit advanced stages of prostate cancer.RelA-Induced Interferon Response Negatively Regulates ProliferationConsequence of the tumor-associated conversion to cyclin D1bThe HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cellsAdvanced neuroendocrine prostate tumors regress to stemnessAndrogen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Palbociclib: first global approval.RB Loss Promotes Prostate Cancer Metastasis.A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.Capsaicin: a novel radio-sensitizing agent for prostate cancer.The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Cell cycle-coupled expansion of AR activity promotes cancer progression.CDK4/6 inhibition is more active against the glioblastoma proneural subtype.Differential impact of RB status on E2F1 reprogramming in human cancer.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cellsA patient-derived explant (PDE) model of hormone-dependent cancer
P2860
Q26865888-8C55D8A8-B39C-48B4-BCA1-7A52CF587876Q27022821-3DB397E0-4740-4DCF-AD8B-BEF966CEC44EQ27852814-9298260E-3B55-4028-960B-4FF90B9F5B5AQ27853170-D9995A74-6DC5-4EC9-B178-61AB85590AD6Q33614544-7DD65D01-B035-4832-B6E9-1A1E90AE744EQ33638023-F44C23FF-EE1F-4976-AFC7-D819C057E427Q33907588-884F8222-183F-4020-BA32-671064C1274CQ34004428-EDD33488-ACE9-4F88-8A77-69FC18F529C9Q34460347-16BE547C-2428-48A7-9B0C-044D8EE6ED61Q34617627-D0A210ED-6F74-4BDB-9CDD-37107EA2FE42Q35099127-E5939645-A513-41B2-90B5-F2B78F1A753BQ35804406-4E1FD7CA-ED43-4F0D-898C-3FCB981F0F37Q35822584-B354A13F-72F8-4F82-B8D9-727FE43B5C23Q36309425-319AF24E-5E53-4F4A-8916-A2560BA9F810Q36332128-BF95712E-4467-4F96-8DF5-971999A6FA61Q37682137-A00FCB71-9E48-4CDE-B99B-C2B9B1F8B5B2Q38232184-16C20EEE-F297-4C30-AA94-4053F83B6721Q38384741-65A819B6-A859-4649-A1EF-CB85E201D182Q38727367-63A3E91D-0198-4C3D-8E44-4C794E1C3647Q38740513-AC2ACC4F-5DF0-4CA1-AEEB-FAC37375835CQ38760366-D45C8662-408C-44B4-B05F-8D004B0B901DQ38871799-A125DAE9-3201-4CB8-B0C1-DE01D890372BQ38895320-CD92D19D-9C30-4F53-838F-638F08A4B45FQ38948728-2E7FF12C-8278-412A-8891-25514AD5B45CQ38962238-9B20CC0A-1110-476B-822A-43A2DAA43187Q39183079-D9C5188C-70CC-4AAA-8462-CA68006B378AQ40565537-3830F960-EE74-482B-9FC3-B0645012DF17Q41548769-63F9154B-86A7-455D-9B76-85FF36170C93Q46068832-FEA4ADFE-1591-41D9-9F15-C1694F4200EAQ47316489-7C7B2B1F-7065-47C5-A91F-970FA49AD22FQ53685801-77773C9D-896C-4E5E-8A95-99D6D9E67F32Q58572503-D61E2927-C307-4E1C-B743-83A334D1CA71Q58772979-F4FD0A9F-D8C4-4FA9-A82B-031B7CC59910
P2860
Targeting cell cycle and hormone receptor pathways in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting cell cycle and hormone receptor pathways in cancer.
@en
Targeting cell cycle and hormone receptor pathways in cancer.
@nl
type
label
Targeting cell cycle and hormone receptor pathways in cancer.
@en
Targeting cell cycle and hormone receptor pathways in cancer.
@nl
prefLabel
Targeting cell cycle and hormone receptor pathways in cancer.
@en
Targeting cell cycle and hormone receptor pathways in cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting cell cycle and hormone receptor pathways in cancer
@en
P2093
A K McClendon
C D Lallas
C E S Comstock
E J Trabulsi
J F Goodwin
L G Gomella
M A Augello
M J Schiewer
P2860
P2888
P304
P356
10.1038/ONC.2013.83
P407
P577
2013-05-27T00:00:00Z